Clinical Question : A 43 year old male presents for follow-up after completing 6 months of apixaban 5mg for a first unprovoked proximal deep vein thrombosis of the left lower extremity. He has no identifiable provoking risk factors such as no recent surgery, immobilization, trauma, or long-distance travel, no active cancer, no known thrombophilia, and no antiphospholipid syndrome. His bleeding risk is low, no prior GI bleeding, normal renal function, no antiplatelet use, and hemoglobin is 14.2 g/dL. The team has decided to continue extended anticoagulation given his high recurrence risk, but he asks whether a lower dose would be equally effective and safer than continuing his current full dose.

PICO Question : In adults with a first unprovoked proximal DVT or PE who have completed 3-6 months of initial anticoagulation and have low bleeding risk, does reduced-dose extended DOAC therapy compared with full-dose DOAC therapy or discontinuation reduce recurrent VTE while minimizing major bleeding, mortality and adverse events?

P	I	C	O
Unprovoked VTE	Reduced dose DOAC therapy	Full dose DOAC	Recurrent VTE
Unprovoked DVT	Low dose DOAC	Standard dose DOAC	DVT recurrence
Unprovoked PE	Apixaban 2.5mg	Apixaban 5mg	PE recurrence
Unprovoked Venous thromboembolism	Rivaroxaban 10mg daily	Rivaroxaban 20mg	Major bleeding
Secondary prevention of VTE	Extended low intensity anticoagulation	Therapeutic dose	Clinically relevant non-major bleeding
	Direct Oral anticoagulation	Secondary prevention	Net clinical benefit
	Reduced intensity anticoagulation	Standard intensity anticoagulation	Mortality
			Adverse events

Search Strategy and Databases Used: 

(unprovoked VTE OR unprovoked DVT OR unprovoked pulmonary embolism) AND (reduced dose DOAC OR low dose DOAC OR reduced intensity anticoagulation)  AND (full dose DOAC OR standard dose DOAC OR therapeutic dose) AND (recurrent VTE OR major bleeding OR clinically relevant non-major bleeding OR mortality OR net clinical benefit OR adverse events)

(unprovoked Pulmonary embolism OR unprovoked deep vein thrombosis OR unprovoked venous thromboembolism) AND (reduced dose OR low dose) AND (standard dose OR therapeutic dose) AND (bleeding OR recurrence PE OR recurrence DVT OR recurrence VTE OR mortality OR adverse events)

PubMed

• Filters: in the last 15 years, Meta-Analysis, Randomized Controlled Trial, Systematic Review, English, Humans, Adult: 19-44 years, MEDLINE → Initially 2 articles then 99 results with broaden terms 
• Chosen 3 articles 

Google Scholar 

• Filters: Since 2016 -2026, review articles, sort by relevance  → 836 
• Chosen 2 articles 

Cochrane Library 

• Filters: Cochrane Reviews, Trials → 1
• Chose 0 articles 

After applying my initial PubMed search terms, only 2 articles were returned because the search was too narrow. I then broadened the timeline to 15 years and expanded my PubMed search terms while still keeping the search aligned with my PICO question. I screened the titles and abstracts in the first 5 pages of results, and removed studies that did not directly answer my clinical question. I had difficulty narrowing down because many of the articles focused on atrial fibrillation, orthopedic prophylaxis, acute VTE treatment only, warfarin-only therapy, pediatric patients, or did not report both recurrent VTE and bleeding outcomes. These were difficult to apply to my PICO and were excluded. I also excluded articles that were mainly guideline summaries or general reviews without direct outcome data. I prioritized randomized controlled trials, systematic reviews, and meta-analyses because these provide the strongest evidence for comparing reduced-dose and full-dose DOAC therapy during the extended treatment phase. I selected these five articles because they directly evaluate outcomes relevant to my clinical question, including recurrent VTE, major bleeding, clinically relevant non-major bleeding, mortality, and net clinical benefit. The selected studies include landmark trials for apixaban and rivaroxaban, a newer head-to-head trial comparing reduced-dose and full-dose DOAC therapy, and recent pooled evidence that helps clarify the risk-benefit balance. Together, these articles provide the most clinically useful evidence for determining whether reduced-dose DOAC therapy can provide adequate protection against recurrent VTE while lowering bleeding risk during extended anticoagulation.

Article 1: Apixaban for extended treatment of venous thromboembolism

Agnelli G, Buller HR, Cohen A, et al. Apixaban for extended treatment of venous thromboembolism. N Engl J Med. 2013;368(8):699-708. doi:10.1056/NEJMoa1207541

Abstract

Background: Apixaban, an oral factor Xa inhibitor that can be administered in a simple, fixed-dose regimen, may be an option for the extended treatment of venous thromboembolism.

Methods: In this randomized, double-blind study, we compared two doses of apixaban (2.5 mg and 5 mg, twice daily) with placebo in patients with venous thromboembolism who had completed 6 to 12 months of anticoagulation therapy and for whom there was clinical equipoise regarding the continuation or cessation of anticoagulation therapy. The study drugs were administered for 12 months.

Results: A total of 2486 patients underwent randomization, of whom 2482 were included in the intention-to-treat analyses. Symptomatic recurrent venous thromboembolism or death from venous thromboembolism occurred in 73 of the 829 patients (8.8%) who were receiving placebo, as compared with 14 of the 840 patients (1.7%) who were receiving 2.5 mg of apixaban (a difference of 7.2 percentage points; 95% confidence interval [CI], 5.0 to 9.3) and 14 of the 813 patients (1.7%) who were receiving 5 mg of apixaban (a difference of 7.0 percentage points; 95% CI, 4.9 to 9.1) (P<0.001 for both comparisons). The rates of major bleeding were 0.5% in the placebo group, 0.2% in the 2.5-mg apixaban group, and 0.1% in the 5-mg apixaban group. The rates of clinically relevant nonmajor bleeding were 2.3% in the placebo group, 3.0% in the 2.5-mg apixaban group, and 4.2% in the 5-mg apixaban group. The rate of death from any cause was 1.7% in the placebo group, as compared with 0.8% in the 2.5-mg apixaban group and 0.5% in the 5-mg apixaban group.

Conclusions: Extended anticoagulation with apixaban at either a treatment dose (5 mg) or a thromboprophylactic dose (2.5 mg) reduced the risk of recurrent venous thromboembolism without increasing the rate of major bleeding. 

• This article is a multicenter, randomized, double-blind, placebo-controlled trial. I chose this study because it is the landmark trial that established apixaban 2.5 mg BID as a reduced-dose option for extended VTE treatment after completion of initial anticoagulation. Although it was published in 2013, I included it because it directly answers an important part of my PICO question and remains one of the foundational studies for reduced-dose apixaban use. The study is especially relevant to my patient because it included 2,482 patients who had already completed 6 to 12 months of anticoagulation, and most participants had unprovoked VTE, which closely matches my patient’s situation. However, this trial was not designed to prove that apixaban 2.5 mg BID is equivalent to apixaban 5 mg BID. It mainly showed that both doses were effective compared with placebo and had low rates of major bleeding.

Key Findings:

• The reduced-dose and full-dose apixaban groups had the same recurrent VTE/VTE-related death rate. This supports that apixaban 2.5 mg BID still provided strong clot protection during extended treatment.
• The main safety finding was reassuring because major bleeding was very low with both apixaban doses. This matters because bleeding risk is one of the biggest concerns when continuing anticoagulation long term.
• Clinically relevant non-major bleeding was numerically lower with apixaban 2.5 mg compared with apixaban 5 mg. This supports the idea that the reduced dose may lower bleeding burden while still maintaining protection.
• The main limitation is that this trial compared both apixaban doses to placebo, not directly against each other. So, it supports reduced-dose apixaban as an effective option, but it does not prove true equivalence between the reduced and full dose.
• This was a multinational trial, so the findings are broadly applicable, but it was not specific to U.S. practice. Cultural and language differences are less likely to affect objective outcomes such as recurrent VTE and bleeding. However, healthcare access, medication cost, insurance coverage, and follow-up may affect how easily reduced-dose apixaban can be continued long term in a U.S. outpatient setting. I still included this study because apixaban is commonly used in the United States, and this trial is the landmark study supporting reduced-dose apixaban for extended VTE treatment.

Article 2: Rivaroxaban or Aspirin for Extended Treatment of Venous Thromboembolism

Weitz JI, Lensing AWA, Prins MH, et al. Rivaroxaban or Aspirin for Extended Treatment of Venous Thromboembolism. N Engl J Med. 2017;376(13):1211-1222. doi:10.1056/NEJMoa1700518

Abstract

Background: Although many patients with venous thromboembolism require extended treatment, it is uncertain whether it is better to use full- or lower-intensity anticoagulation therapy or aspirin.

Methods: In this randomized, double-blind, phase 3 study, we assigned 3396 patients with venous thromboembolism to receive either once-daily rivaroxaban (at doses of 20 mg or 10 mg) or 100 mg of aspirin. All the study patients had completed 6 to 12 months of anticoagulation therapy and were in equipoise regarding the need for continued anticoagulation. Study drugs were administered for up to 12 months. The primary efficacy outcome was symptomatic recurrent fatal or nonfatal venous thromboembolism, and the principal safety outcome was major bleeding.

Results: A total of 3365 patients were included in the intention-to-treat analyses (median treatment duration, 351 days). The primary efficacy outcome occurred in 17 of 1107 patients (1.5%) receiving 20 mg of rivaroxaban and in 13 of 1127 patients (1.2%) receiving 10 mg of rivaroxaban, as compared with 50 of 1131 patients (4.4%) receiving aspirin (hazard ratio for 20 mg of rivaroxaban vs. aspirin, 0.34; 95% confidence interval [CI], 0.20 to 0.59; hazard ratio for 10 mg of rivaroxaban vs. aspirin, 0.26; 95% CI, 0.14 to 0.47; P<0.001 for both comparisons). Rates of major bleeding were 0.5% in the group receiving 20 mg of rivaroxaban, 0.4% in the group receiving 10 mg of rivaroxaban, and 0.3% in the aspirin group; the rates of clinically relevant nonmajor bleeding were 2.7%, 2.0%, and 1.8%, respectively. The incidence of adverse events was similar in all three groups.

Conclusions: Among patients with venous thromboembolism in equipoise for continued anticoagulation, the risk of a recurrent event was significantly lower with rivaroxaban at either a treatment dose (20 mg) or a prophylactic dose (10 mg) than with aspirin, without a significant increase in bleeding rates

• This article is a multicenter, randomized, double-blind, phase 3 trial. I chose this study because it is one of the landmark trials supporting reduced-dose rivaroxaban 10 mg daily for extended VTE treatment after completion of initial anticoagulation. It is relevant to my PICO because it compares lower-dose rivaroxaban with full-dose rivaroxaban and aspirin during the extended treatment phase while evaluating recurrent VTE and bleeding outcomes. This study also complements AMPLIFY-EXT because it provides evidence for rivaroxaban, while AMPLIFY-EXT provides evidence for apixaban. However, this trial has limitations and should be interpreted carefully. EINSTEIN CHOICE was mainly designed to compare each rivaroxaban dose with aspirin, not to prove that rivaroxaban 10 mg is equivalent to rivaroxaban 20 mg. The study included 3,365 patients who had completed 6 to 12 months of anticoagulation, but only about 40% had unprovoked VTE. Therefore, it is useful because it evaluates a medication and dosing strategy commonly used in practice, but it does not perfectly match my patient, who has a first unprovoked proximal DVT.

Key Findings:

• Rivaroxaban 10 mg daily had a similar recurrent VTE rate compared with rivaroxaban 20 mg daily during extended treatment. This supports that the lower dose may still provide adequate protection after the initial anticoagulation period.
• In the unprovoked VTE subgroup, recurrence stayed low with both rivaroxaban doses. This is important because unprovoked VTE patients have a higher long-term recurrence risk.
• Major bleeding was low with both rivaroxaban doses, and clinically relevant non-major bleeding was numerically lower with the 10 mg dose compared with the 20 mg dose. This supports the safety advantage of the reduced dose.
• The main limitation is that the trial was mainly designed to compare rivaroxaban with aspirin, not to prove rivaroxaban 10 mg is equivalent to rivaroxaban 20 mg. Also, only about 40% of patients had unprovoked VTE, so it does not perfectly match my patient.

Article 3: Extended treatment of venous thromboembolism with reduced-dose versus full-dose direct oral anticoagulants in patients at high risk of recurrence: a non-inferiority, multicentre, randomised, open-label, blinded endpoint trial

Abstract

Couturaud F, Schmidt J, Sanchez O, et al. Extended treatment of venous thromboembolism with reduced-dose versus full-dose direct oral anticoagulants in patients at high risk of recurrence: a non-inferiority, multicentre, randomised, open-label, blinded endpoint trial. Lancet. 2025;405(10480):725-735. doi:10.1016/S0140-6736(24)02842-3 

Background: In patients with venous thromboembolism at high risk of recurrence for whom extended treatment with direct oral anticoagulants has been indicated, the optimal dose is unknown. We aimed to assess efficacy and safety of reduced-dose versus full-dose direct oral anticoagulants in patients in whom extended anticoagulation has been indicated.

Methods: RENOVE was a non-inferiority, investigator-initiated, multicentre, randomised, open-label, blinded endpoint trial done in 47 hospitals in France. Ambulatory patients aged 18 years or older with acute symptomatic venous thromboembolism (pulmonary embolism or proximal deep vein thrombosis) who had received 6–24 uninterrupted months of full-dose anticoagulation and for whom extended anticoagulation has been indicated were eligible. Eligible participants were categorised as having either a first unprovoked venous thromboembolism, recurrent venous thromboembolism, presence of persistent risk factors, or other clinical situations considered to be a high risk of recurrence. Participants were randomly assigned (1:1) to receive oral treatment with either a reduced dose of apixaban (2·5 mg twice daily) or rivaroxaban (10 mg once daily) or a full dose of apixaban (5 mg twice daily) or rivaroxaban (20 mg once daily) using a centralised randomisation procedure with an interactive web response system. The sequence generation method was a computerised random number generator and was balanced by blocks of different sizes. Randomisation was stratified by centre, type of direct oral anticoagulant, and antiplatelet drug. Physicians and participants were unmasked to treatment allocation; recurrent venous thromboembolism, clinically relevant bleeding, and all-cause death were adjudicated by an independent committee blinded to treatment allocation. The primary outcome was symptomatic recurrent venous thromboembolism, including recurrent fatal or non-fatal pulmonary embolism or isolated proximal deep vein thrombosis (non-inferiority hypothesis 90% power to exclude a hazard ratio [HR] of 1·7). The primary outcome and first two secondary outcomes were included in a hierarchical testing procedure. This trial is registered with ClinicalTrials.gov, NCT03285438.

Findings: From Nov 2, 2017, to July 6, 2022, 2768 patients were enrolled and randomly assigned to the reduced-dose group (n=1383) or the full-dose group (n=1385). 970 (35·0%) participants were female, 1797 (65·0%) were male, and one (<0·1%) had sex not reported. Median follow-up was 37·1 months (IQR 24·0–48·3). Recurrent venous thromboembolism occurred in 19 of 1383 patients in the reduced-dose group (5-year cumulative incidence 2·2% [95% CI 1·1–3·3]) versus 15 of 1385 patients in the full-dose group (5-year cumulative incidence 1·8% [0·8–2·7]; adjusted HR 1·32 [95% CI 0·67–2·60]; absolute difference 0·40% [95% CI –1·05 to 1·85]; p=0·23 for non-inferiority). Major or clinically relevant bleeding occurred in 96 patients in the reduced-dose group (5-year cumulative incidence 9·9% [95% CI 7·7–12·1]) and 154 patients in the full-dose group (5-year cumulative incidence 15·2% [12·8–17·6]; adjusted HR 0·61 [95% CI 0·48–0·79]). 1136 (82·1%) of 1383 patients in the reduced-dose group and 1150 (83·0%) of 1385 in the full-dose group had an adverse event; 374 (27·0%) patients in the reduced-dose group and 420 (30·3%) in the full-dose group has a serious adverse event. 35 (5-year cumulative incidence 4·3% [95% CI 2·6–6·0]) patients in the reduced-dose group and 54 (5-year cumulative incidence 6·1% [4·3–8·0]) patients in the full-dose group died during the study period.

Interpretation: In patients with venous thromboembolism requiring extended anticoagulation, reduction of the direct oral anticoagulant dose did not meet the non-inferiority criteria. However, the low recurrence rates in both groups and substantial reduction of clinically relevant bleeding with the reduced dose could support this regimen as an option. Further research will be needed to identify subgroups for whom the anticoagulation dose should not be reduced.

• This article is a multicenter, randomized, open-label, blinded-endpoint, non-inferiority trial. I chose this study because it is the most directly relevant article to my PICO question. Unlike AMPLIFY-EXT and EINSTEIN CHOICE, which compared reduced-dose and full-dose DOACs to placebo or aspirin, RENOVE directly compared reduced-dose DOAC therapy with full-dose DOAC therapy during extended VTE treatment. This study included 2,768 patients who had completed 6 to 24 months of full-dose anticoagulation and were considered to need extended anticoagulation due to high recurrence risk. This makes it clinically relevant to my patient, who has a first unprovoked proximal DVT and is being considered for long-term anticoagulation. However, the study population was not a perfect match because it also included patients with recurrent VTE and persistent risk factors, not only first unprovoked VTE.

Key Findings:

• Couturaud et al. (2025), the RENOVE trial, directly tested reduced-dose versus full-dose DOAC therapy in patients who still needed extended anticoagulation. The patients were considered higher risk for recurrence, so this study is very relevant to the extended-treatment decision.
• Reduced-dose therapy did not meet the formal non-inferiority criteria. Recurrent VTE was low in both groups, and the absolute difference was small, but the study could not statistically prove the reduced dose was non-inferior.
• The strongest benefit was lower bleeding with reduced-dose therapy. Major or clinically relevant non-major bleeding was clearly lower in the reduced-dose group, which is clinically important for patients staying on anticoagulation long term.
• The main limitation is that the study could not identify which patients should stay on full-dose therapy. It also included different recurrence-risk groups, so the results support reduced-dose therapy as an option, but not as an automatic choice for every patient.

Foreign Study Policy:

• This study was conducted in France, so it should be applied to a U.S. patient with some caution. Cultural differences are less likely to directly affect biologic outcomes such as recurrent VTE and bleeding, but they may influence patient preferences, comfort with long-term anticoagulation, and shared decision-making. Socially, France and the United States may differ in follow-up access, specialist availability, and how anticoagulation care is coordinated, which can affect adherence and how quickly bleeding symptoms are reported. Economically, medication cost, insurance coverage, pharmacy access, prior authorization, and copays may be different in the United States and may affect whether a patient can realistically continue DOAC therapy long term. Language is not a major limitation in interpreting this study because it was published in English and measured objective clinical outcomes, but patient counseling in U.S. practice should still be provided in the patient’s preferred language. I included this study because it is the first head-to-head randomized trial directly comparing reduced-dose and full-dose DOAC therapy, and apixaban and rivaroxaban are both commonly used in U.S. practice.

Article 4: Efficacy and safety of reduced-dose versus full-dose direct oral anticoagulants for extended treatment of venous thromboembolism: A meta-analysis with trial sequential analysis and reconstructed time-to-event data

Ibrahim A, Shalabi L, Zreigh S, et al. Efficacy and safety of reduced-dose versus full-dose direct oral anticoagulants for extended treatment of venous thromboembolism: A meta-analysis with trial sequential analysis and reconstructed time-to-event data. Thromb Res. 2025;254:109476. doi:10.1016/j.thromres.2025.109476

Abstract

Background: While current guidelines recommend extended therapeutic anticoagulation for venous thromboembolism (VTE), the optimal dosing strategy for direct oral anticoagulants (DOACs) remains uncertain, particularly in cancer-associated VTE. This meta-analysis evaluates the efficacy and safety of reduced-dose versus full-dose DOACs for extended VTE treatment.

Methods: We conducted a comprehensive search of major electronic databases through April 2025 for randomized controlled trials (RCTs) comparing reduced-dose versus full-dose DOACs for VTE treatment. Pooled risk ratios (RR) with 95 % confidence intervals (CI) were calculated using random-effects models. Time-to-event data were reconstructed from Kaplan-Meier curves. Trial sequential analysis (TSA) was employed to assess the conclusiveness of the evidence.

Results: Our analysis included five RCTs involving 8781 patients. Reduced-dose DOACs were associated with comparable efficacy to full-dose therapy in preventing recurrent VTE (RR, 0.94; 95 % CI, 0.68-1.29; P = 0.70), supported by time-to-event analysis (HR, 0.89; 95 % CI 0.78-1.02; p = 0.10). However, reduced-dose regimens significantly reduced major or clinically relevant non-major bleeding (RR, 0.71; 95 % CI 0.61-0.82; P < 0.0001), with consistent findings on Kaplan-Meier analysis (HR, 0.61; 95 % CI 0.57-0.66; P < 0.001). Subgroup analyses showed consistent results in patients with and without active cancer, and also across different DOAC types (apixaban and rivaroxaban). No differences were observed in all-cause mortality. TSA confirmed sufficient evidence for both efficacy and safety outcomes.

Conclusion: Reduced-dose DOACs were as effective as full-dose regimens in preventing recurrent VTE, with a better safety profile, suggesting they may be preferred for patients requiring extended anticoagulation, especially those at high risk of recurrence.

This article is a systematic review and meta-analysis of randomized controlled trials. I chose this study because it directly compares reduced-dose versus full-dose DOAC therapy for extended VTE treatment, which matches my PICO question. It included 5 randomized controlled trials with 8,781 patients, making it useful for looking at the overall balance between recurrent VTE prevention and bleeding risk.

I also chose this study because it used trial sequential analysis and reconstructed time-to-event data, which adds more strength than a basic meta-analysis. This helps show whether the available evidence is strong enough or whether more data may still be needed. The study found no significant increase in recurrent VTE with reduced-dose DOACs compared with full-dose therapy, while major or clinically relevant non-major bleeding was significantly lower. However, it should be applied carefully to my patient because some included trials involved cancer-associated VTE, while my patient does not have active cancer.

Key Findings:

• The recurrent VTE finding was strong because the authors graded it as high-certainty evidence, with no important heterogeneity between trials. The absolute difference was very small, about 1 fewer recurrent VTE event per 1,000 patients with reduced-dose therapy compared with full-dose therapy.
• The bleeding benefit was more clinically meaningful than the recurrence difference. Reduced-dose therapy led to about 25 fewer major or clinically relevant non-major bleeding events per 1,000 patients compared with full-dose therapy.
• The trial sequential analysis strengthened the results by showing that reduced-dose therapy is unlikely to cause a clinically meaningful increase in recurrent VTE and that the bleeding reduction is likely a true benefit.
• The main limitation is that the included trials had different designs and patient populations, including some patients with active cancer. Because of this, the findings support reduced-dose therapy, but they still need to be applied based on the individual patient’s recurrence and bleeding risk.

Article 5: Reduced-Dose Versus Full-Dose Direct Oral Anticoagulants in the Extended Treatment of Venous Thromboembolism: A Systematic Review and Meta-Analysis

Abstract

Akhtar M, Nabi R, Saadia S, et al. Reduced-Dose Versus Full-Dose Direct Oral Anticoagulants in the Extended Treatment of Venous Thromboembolism: A Systematic Review and Meta-Analysis. Cardiovasc Drugs Ther. 2026;40(3):943-951. doi:10.1007/s10557-025-07759-1

Purpose: The optimal dosing strategy for direct oral anticoagulants (DOACs) in extended treatment of venous thromboembolism (VTE) remains debated, particularly in balancing efficacy and bleeding risk.

Methods: A systematic review and meta-analysis was performed to compare reduced-dose versus full-dose DOACs for extended VTE treatment. Databases including PubMed, Embase, and Cochrane Library were searched from inception to March 2025 for randomized controlled trials (RCTs) involving adult patients treated with different DOAC doses for VTE. Primary outcomes were recurrent VTE, major or clinically relevant non-major bleeding, and all-cause mortality. Subgroup analysis was conducted by DOAC type (apixaban vs. rivaroxaban).

Results: Pooled data from 4 studies involving 8421 patients showed no statistically significant difference in recurrent VTE risk between reduced-dose and full-dose DOACs (RR = 0.94; 95% CI, 0.64-1.37; p = 0.75). Bleeding events were significantly lower in the reduced-dose group compared to the full-dose group (RR = 0.71; 95% CI, 0.61-0.82, p < 0.00001). All-cause mortality did not differ significantly between groups (RR = 0.80; 95% CI, 0.54-1.18; p = 0.25). Subgroup analysis showed consistent findings across DOAC type, with no significant interaction effects.

Conclusion: Reduced-dose DOACs appear to be as effective as full-dose DOACs in preventing VTE, with a favorable safety profile due to reduced bleeding risk. These findings support reduced-dose DOACs as a viable option for extended anticoagulation in VTE patients.

This article is a systematic review and meta-analysis of randomized controlled trials. I chose this study as supportive evidence because it directly compares reduced-dose versus full-dose DOAC therapy for extended VTE treatment, which matches my PICO question. It included 4 randomized controlled trials with 8,421 patients and evaluated recurrent VTE, major or clinically relevant non-major bleeding, and all-cause mortality. This study is useful because it provides recent pooled evidence and includes subgroup analysis by DOAC type, specifically apixaban versus rivaroxaban. This helps support whether the reduced-dose strategy is consistent across the two DOACs most relevant to my patient. 

Key Findings:

• The recurrent VTE finding was consistent across the included trials, with no major heterogeneity. Reduced-dose DOAC therapy did not show a clear loss of protection compared with full-dose therapy.
• The main benefit was lower bleeding with reduced-dose therapy. This is important because extended anticoagulation is long term, and bleeding risk can affect safety, adherence, and whether patients are willing to continue therapy.
• The subgroup analysis showed similar results for both apixaban and rivaroxaban, with no significant difference between the two DOAC types. This supports that the reduced-dose approach may apply to both medications, not just one.
• The main limitation is that only 4 RCTs were included, and only apixaban and rivaroxaban were studied. About 28.4% of patients had active cancer, follow-up length varied between studies, and publication bias could not be assessed because the number of trials was small.

Summary of Evidence

Author (Date)	Level of Evidence	Sample/setting	Outcomes studied	Key Findings	Limitations and Biases
Agnelli et al. (2013)	Randomized controlled trial, multicenter, double-blind, placebo-controlled	2,482 patients with VTE who completed 6–12 months of anticoagulation and were randomized to apixaban 2.5 mg BID, apixaban 5 mg BID, or placebo for 12 months.Most patients had unprovoked VTE	Recurrent VTE or VTE-related death, major bleeding, clinically relevant non-major bleeding, and all-cause mortality.	Reduced-dose apixaban and full-dose apixaban had the same recurrent VTE/VTE related death rate at 1.7%.Both apixaban doses provided much better clot protection than placebo.Major bleeding was very low with both apixaban doses and was not higher than placebo.Clinically relevant non-major bleeding was numerically lower with apixaban 2.5 mg BID compared with apixaban 5 mg BID.This supports reduced-dose apixaban as an effective extended-treatment option, but not as proven equivalent to full-dose apixaban.	The trial compared each apixaban dose to placebo, not directly against each other.Follow-up was only 12 monthsThe study was industry funded by Bristol-Myers Squibb and Pfizer.Patients who were older, low body weight, or had significant renal impairment were limited, so the results may not apply to every patient.
Weitz et al. (2017)	Randomized controlled trial, multicenter, double-blind, phase 3	3,365 patients across 244 sites in 31 countries who completed 6–12 months of anticoagulation Randomized to rivaroxaban 20 mg daily, rivaroxaban 10 mg daily, or aspirin 100mg40% of patients had unprovoked VTE.	Recurrent Fatal or nonfatal VTE, major bleeding, clinically relevant non-major bleeding, mortality and adverse events.	Rivaroxaban 10 mg daily had a similar recurrent VTE rate compared with rivaroxaban 20 mg daily during extended treatment.In the unprovoked VTE subgroup, recurrence stayed low with both rivaroxaban doses.Major bleeding was low with both rivaroxaban doses.Clinically relevant non-major bleeding was numerically lower with rivaroxaban 10 mg compared with rivaroxaban 20 mg.The findings support reduced-dose rivaroxaban as a reasonable extended-treatment option, but not as proven equivalent to full-dose rivaroxaban.	The study was mainly designed to compare rivaroxaban with aspirin, not rivaroxaban 10 mg directly against rivaroxaban 20 mg.Only about 40% of patients had unprovoked VTE, so it does not perfectly match my patient.Patients were included only if there was clinical equipoise about continuing anticoagulation, so the highest-risk patients may not be fully represented.Follow-up was about 12 months.The study was funded by Bayer, so industry funding should be considered.
Couturaud et. al (2025)	Randomized controlled trial, multicenter, open-label, blinded-endpoint, non-inferiority trial	2,768 patients at 47 hospitals in France. Patients were 18 years or older, had symptomatic PE or proximal DVT, had completed 6 to 24 months of uninterrupted full-dose anticoagulation, and were considered to need extended anticoagulation due to high recurrence risk. Patients randomized to reduced-dose apixaban 2.5 mg BID or rivaroxaban 10 mg daily versus full-dose apixaban 5 mg BID or rivaroxaban 20 mg daily.  Median follow-up was 37.1 months.	Recurrent VTE, major or clinically relevant non-major bleeding, all-cause mortality, adverse events, and net clinical benefit.	Reduced-dose therapy did not meet the formal non-inferiority criteria.Recurrent VTE was low in both groups, with only a small absolute difference between reduced-dose and full-dose therapy.The strongest benefit was lower bleeding with reduced-dose therapy.Major or clinically relevant non-major bleeding was clearly lower in the reduced-dose group.This supports reduced-dose therapy as an option, but it does not prove reduced-dose therapy is definitely non-inferior to full-dose therapy.	The study was open-label, so patients and providers knew the assigned dose.Outcomes were reviewed by a blinded independent committee, which helps reduce bias.The study was conducted only in France, so it should be applied to U.S. practice with some caution.The population included different recurrence-risk groups, including first unprovoked VTE, recurrent VTE, and persistent risk factors.The study could not identify which specific patients should remain on full-dose therapy.Event rates were lower than expected, which made it harder for the trial to prove non-inferiority.
Ibrahim et al. (2025)	Systematic review and meta-analysis of RCTs with trial sequential analysis	meta-analysis included 5 randomized controlled trials with 8,781 patients comparing reduced-dose versus full-dose DOAC therapy for extended VTE treatment.  4,395 patients were assigned to reduced-dose DOAC therapy and 4,386 were assigned to full-dose therapy.	Recurrent VTE, recurrent PE, recurrent DVT, major or clinically relevant non-major bleeding, major bleeding, clinically relevant non-major bleeding, all-cause mortality, adverse events, serious adverse events, and adverse events leading to treatment discontinuation.	The recurrent VTE outcome was graded as high-certainty evidence.The absolute difference in recurrent VTE was very small, about 1 fewer event per 1,000 patients with reduced-dose therapy.The bleeding benefit was more clinically meaningful, with about 25 fewer major or clinically relevant non-major bleeding events per 1,000 patients.Trial sequential analysis strengthened confidence that reduced-dose therapy is unlikely to meaningfully increase recurrent VTE risk.Subgroup findings were generally consistent across apixaban and rivaroxaban and in patients with and without active cancer.	The meta-analysis included trials with different designs and patient populations.Some trials were direct dose comparisons, while others originally compared treatment to placebo or aspirin.Some included patients had cancer-associated VTE, which does not match my patient.Most studies had only about 12 months of follow-up.The meta-analysis is limited by the quality and design differences of the included trials.
Akhtar et al. (2026)	Systematic review and meta-analysis of randomized controlled trials	4 randomized controlled trials with 8,421 patients comparing reduced-dose versus full-dose DOAC therapy for extended VTE treatment. Total of 4,216 patients were in the reduced-dose DOAC group and 4,205 were in the full-dose DOAC group.28.4% of patients had active cancer, and follow-up ranged from about 12 months to 37.1 months.	Recurrent VTE, major or clinically relevant non-major bleeding, all-cause mortality, and subgroup analysis by DOAC type.	Reduced-dose DOAC therapy did not significantly increase recurrent VTE compared with full-dose therapy. The pooled RR for recurrent VTE was 0.94. Major or clinically relevant non-major bleeding was significantly lower with reduced-dose therapy, with a RR of 0.71. There was no significant difference in all-cause mortality. Subgroup analysis by DOAC type showed consistent findings for apixaban and rivaroxaban, with no significant interaction effect.	Only 4 RCTs were included, so the evidence base is still limited.This article overlaps with Ibrahim et al. because several of the same trials were included.Only apixaban and rivaroxaban were studied, so the results cannot automatically be applied to other DOACs.About 28.4% of patients had active cancer, which does not match my patient.Follow-up length varied across studies.Publication bias could not be assessed because the number of included trials was small.

Conclusions

Article 1 – Agnelli et al. (2013)
Agnelli et al. concluded that both reduced-dose apixaban 2.5 mg BID and full-dose apixaban 5 mg BID were effective for extended VTE prevention compared with placebo. Recurrent VTE or VTE-related death occurred in 1.7% of both apixaban groups compared with 8.8% in the placebo group. Major bleeding was very low in all groups, occurring in 0.2% with apixaban 2.5 mg, 0.1% with apixaban 5 mg, and 0.5% with placebo. This article supports reduced-dose apixaban as an effective extended-treatment option. However, it does not prove that apixaban 2.5 mg is equivalent to apixaban 5 mg because the trial was mainly designed to compare each dose against placebo, not against each other.

Article 2 – Weitz et al. (2017)
Weitz et al. concluded that both rivaroxaban 20 mg daily and rivaroxaban 10 mg daily reduced recurrent VTE compared with aspirin during extended treatment. Recurrent VTE occurred in 1.5% of the rivaroxaban 20 mg group, 1.2% of the rivaroxaban 10 mg group, and 4.4% of the aspirin group. Major bleeding was low across all groups. This trial supports reduced-dose rivaroxaban 10 mg daily as an effective extended-treatment option. However, like article 1, it was not powered to prove that the reduced dose was equivalent to the full dose because the main comparison was rivaroxaban versus aspirin.

Article 3 – Couturaud et al. (2025)
Couturaud et al. conducted the most directly relevant trial because it directly compared reduced-dose DOAC therapy with full-dose DOAC therapy. Recurrent VTE was low in both groups, occurring in 2.2% of the reduced-dose group and 1.8% of the full-dose group at 5 years. However, the trial did not meet the formal non-inferiority criteria, so it could not statistically prove that reduced-dose therapy was equivalent to full-dose therapy. At the same time, reduced-dose therapy lowered major or clinically relevant non-major bleeding, 9.9% versus 15.2%. This article adds the most nuance to the clinical question because it supports reduced-dose therapy from a safety standpoint, but it also shows that true equivalence has not been fully proven.

Article 4 – Ibrahim et al. (2025)
Ibrahim et al. pooled 5 randomized controlled trials with 8,781 patients and found that reduced-dose DOAC therapy did not significantly increase recurrent VTE compared with full-dose therapy. The pooled RR for recurrent VTE was 0.94. Reduced-dose therapy significantly lowered major or clinically relevant non-major bleeding, with a pooled RR of 0.71. There was no significant difference in all-cause mortality. The trial sequential analysis strengthened confidence that reduced-dose therapy is unlikely to meaningfully increase recurrent VTE risk and supports a real bleeding benefit. However, this meta-analysis included mixed populations, including cancer-associated VTE patients, and pooled trials with different study designs.

Article 5 – Akhtar et al. (2026)
Akhtar et al. included 4 randomized controlled trials with 8,421 patients and reached similar conclusions. Reduced-dose DOAC therapy did not significantly increase recurrent VTE compared with full-dose therapy, with a pooled RR of 0.94. Major or clinically relevant non-major bleeding was significantly lower with reduced-dose therapy, with a pooled RR of 0.71. There was no significant difference in all-cause mortality. Subgroup analysis showed similar findings for apixaban and rivaroxaban. This article supports the same overall trend as Ibrahim et al., but it overlaps with many of the same trials, so I interpreted it as supportive evidence rather than completely independent evidence.

Overarching Conclusion

Overall, the evidence supports reduced dose DOAC therapy as a reasonable option for extended VTE treatment after the initial anticoagulation period. Across the five articles, reduced-dose therapy generally maintained similar protection against recurrent VTE while lowering bleeding risk. However, I would not say reduced-dose therapy is definitely equivalent to full-dose therapy. Agnelli et al. and Weitz et al. support reduced-dose apixaban and rivaroxaban, but they were not designed as true head-to-head dose equivalence trials. Couturaud et al. study was the most direct trial, and it did not meet formal non-inferiority, even though recurrence was low in both groups and bleeding was lower with reduced-dose therapy. The two meta-analyses strengthen the overall evidence, but they include some overlapping trials and mixed patient populations. Therefore, reduced-dose apixaban or rivaroxaban is likely appropriate for many patients who need extended anticoagulation, but the decision should still be individualized.

Clinical Bottom Line

Weight of the Evidence

The overall weight of the evidence favors reduced-dose DOAC therapy for extended VTE treatment, but with caution. The evidence is strong because it includes randomized controlled trials and systematic reviews/meta-analyses. The main strength is consistency: reduced-dose therapy did not show a significant increase in recurrent VTE, while bleeding was consistently lower. The main weakness is that not every study directly compared reduced-dose therapy with full-dose therapy. Agnelli et al., AMPLIFY-EXT trial, compared apixaban doses to placebo, and Weitz et al.,  EINSTEIN CHOICE,  compared rivaroxaban doses to aspirin. Couturaud et al. (2025), the RENOVE trial, was the best direct comparison, but it failed to meet formal non-inferiority. Because of this, reduced-dose therapy is supported by the evidence, but I would not present it as a guaranteed equivalent option for every patient.

Magnitude of Effects

The clearest benefit was the reduction in bleeding. Couturaud et al. (2025), the RENOVE trial, major or clinically relevant non-major bleeding was 9.9% with reduced-dose therapy compared with 15.2% with full-dose therapy. This is an absolute difference of 5.3%, which means about 1 fewer clinically relevant bleeding event for every 19 patients treated with reduced-dose therapy over the study period. For recurrent VTE, the difference was much smaller. In RENOVE, recurrent VTE was 2.2% with reduced-dose therapy compared with 1.8% with full-dose therapy, an absolute difference of only 0.4%. In both meta-analyses, reduced-dose therapy did not significantly increase recurrent VTE. This suggests that the bleeding benefit is more clinically noticeable than any possible difference in clot recurrence.

What Still Needs to Be Explored

More research is still needed to clarify which patients should remain on full-dose DOAC therapy instead of stepping down to a reduced dose. The current evidence supports reduced-dose therapy as a reasonable option, but it does not prove that reduced-dose therapy is the best choice for every patient. Future studies should include larger head-to-head non-inferiority trials that are powered well enough to confirm whether reduced-dose therapy is truly non-inferior to full-dose therapy. This is important because the Couturaud et al. (2025), the RENOVE trial, was the most direct comparison, but it did not meet formal non-inferiority. More long-term data are also needed because many patients continue anticoagulation for several years or indefinitely. Future studies should follow patients beyond 3 to 5 years and should better evaluate subgroups such as patients with recurrent unprovoked VTE, thrombophilia, severe obesity, renal impairment, elevated D-dimer, or residual clot burden. Lastly, more diverse patient populations should be included. More data on Black, Hispanic, Asian, and underserved urban populations would help determine whether the benefits and risks of reduced-dose therapy apply equally across different groups.

Clinical Significance

For my patient, a 43 year old male with a first unprovoked proximal DVT who completed 6 months of apixaban 5 mg BID and has low bleeding risk, stepping down to apixaban 2.5 mg BID is a reasonable option for extended anticoagulation. He has no prior GI bleeding, normal renal function, no antiplatelet use, and stable hemoglobin, so his short-term bleeding risk is low. However, because extended anticoagulation may continue for years, even a modest reduction in bleeding risk can become clinically important over time. I would explain to the patient that the lower dose is not the same as stopping anticoagulation. It is still meant to prevent another clot, but with a lower bleeding risk during the extended treatment phase. I would also be honest that the evidence supports reduced-dose therapy, but one major head-to-head trial did not formally prove non-inferiority. Therefore, the decision should be individualized based on his recurrence risk, bleeding risk, medication access, adherence, and preferences. Before finalizing the plan, I would make sure he can afford the medication, understands that the reduced dose still needs to be taken consistently, and has follow-up to reassess renal function, bleeding risk, recurrence risk, and patient preference.

Social and Cultural Context

This recommendation is generally applicable to underserved urban populations because apixaban and rivaroxaban are commonly used in U.S. outpatient practice and do not require INR monitoring like warfarin. This can be helpful for patients who have barriers to frequent lab visits, such as work schedules, transportation issues, limited clinic access, or unstable insurance. However, DOAC access can still be a major barrier. A reduced dose does not always mean lower cost, so insurance coverage, prior authorization, copays, pharmacy access, and refill delays can affect whether the patient can continue therapy long term. If cost or access becomes a barrier, the priority should be maintaining safe anticoagulation rather than assuming the patient can easily stay on a DOAC.

Health literacy also matters. Some patients may hear “reduced dose” and think the medication is less important or that missed doses are okay. Counseling should be simple and clear: the dose is lower because the patient is now in the extended prevention phase, but the medication still needs to be taken consistently. Patients should also understand bleeding symptoms, when to seek care, and why NSAIDs or heavy alcohol use may increase bleeding risk. Cultural beliefs and patient preferences may also affect adherence. Some patients may want to stop medication once they feel better, especially if they do not understand that unprovoked VTE can recur even after symptoms improve. Counseling should be done in the patient’s preferred language and should include both the benefit of preventing another clot and the risk of bleeding. Therefore, the recommendation is not just “switch to reduced-dose apixaban.” Reduced-dose apixaban 2.5 mg BID is reasonable only if the patient can afford it, understands why continued anticoagulation is needed, can take it consistently, and has access to follow-up.